POTENZA, ALESSIA
 Distribuzione geografica
Continente #
EU - Europa 106
AS - Asia 90
NA - Nord America 78
SA - Sud America 8
AF - Africa 3
Totale 285
Nazione #
US - Stati Uniti d'America 78
IT - Italia 43
HK - Hong Kong 35
SG - Singapore 31
DE - Germania 15
ID - Indonesia 12
CH - Svizzera 11
IE - Irlanda 8
SE - Svezia 7
BR - Brasile 6
NL - Olanda 6
RU - Federazione Russa 5
JP - Giappone 4
AT - Austria 3
CN - Cina 3
ES - Italia 2
FR - Francia 2
GB - Regno Unito 2
GH - Ghana 2
IN - India 2
PE - Perù 2
BD - Bangladesh 1
FI - Finlandia 1
GE - Georgia 1
MA - Marocco 1
TR - Turchia 1
UA - Ucraina 1
Totale 285
Città #
Hong Kong 32
Fairfield 15
Singapore 13
Milan 12
Dublin 8
Jakarta 8
Zurich 7
Ashburn 6
Nuremberg 6
Cambridge 5
Cagliari 4
Frankfurt am Main 4
Princeton 4
Tokyo 4
Wilmington 4
Chicago 3
Ferrara 3
Houston 3
Santa Clara 3
Shanghai 3
Woodbridge 3
Accra 2
Acquafredda 2
Andover 2
Ann Arbor 2
Azzano San Paolo 2
Brescia 2
Las Vegas 2
Lima 2
Montecchio Maggiore 2
Seattle 2
Vienna 2
Basel 1
Belo Horizonte 1
Berlin 1
Bologna 1
Cesano Boscone 1
Ciampino 1
Columbus 1
Congonhal 1
Corridonia 1
Falls Church 1
Fes 1
Geneva 1
Itupeva 1
Lappeenranta 1
Lawrence 1
Lübeck 1
Maceió 1
Munich 1
Nashville 1
Norwalk 1
Oberentfelden 1
Osnago 1
Phoenix 1
Presidente Prudente 1
Rome 1
Tbilisi 1
Toulouse 1
Vila Velha 1
Totale 200
Nome #
Effector T cells co-expressing PD1 and CD39 are enriched in colorectal tumors: implications for cancer immunotherapy 119
TCR Redirected T Cells for Cancer Treatment: Achievements, Hurdles, and Goals 79
CRISPR-based gene disruption and integration of high-avidity, WT1-specific T cell receptors improve antitumor T cell function 17
Correction to: Type I IFNs promote cancer cell stemness by triggering the epigenetic regulator KDM1B (Nature Immunology, (2022), 23, 9, (1379-1392), 10.1038/s41590-022-01290-3) 15
Harnessing T cell exhaustion and trogocytosis to isolate patient-derived tumor-specific TCR 14
Type I IFNs promote cancer cell stemness by triggering the epigenetic regulator KDM1B 14
TIM-3, LAG-3, or 2B4 gene disruptions increase the anti-tumor response of engineered T cells 14
Harnessing the tumor microenvironment to boost adoptive T cell therapy with engineered lymphocytes for solid tumors 13
Revealing and harnessing CD39 for the treatment of colorectal cancer and liver metastases by engineered T cells 12
Epithelial ovarian cancer is infiltrated by activated effector T cells co-expressing CD39, PD-1, TIM-3, CD137 and interacting with cancer cells and myeloid cells 10
Flow cytometry data mining by cytoChain identifies determinants of exhaustion and stemness in TCR-engineered T cells 10
Workflow for high-dimensional flow cytometry analysis of T cells from tumor metastases 8
Totale 325
Categoria #
all - tutte 1.545
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 1.545


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202147 0 0 0 0 0 0 26 5 8 2 3 3
2021/202212 0 2 2 2 0 1 0 0 1 0 0 4
2022/202320 5 5 2 0 0 4 0 0 0 0 2 2
2023/202442 0 0 0 0 11 2 6 7 4 4 3 5
2024/2025204 8 11 6 10 4 48 44 32 39 2 0 0
Totale 325